 |
Finsbury is handling Takeda Pharmaceuticals' fifth bid for rare drug specialist Shire PLC of Dublin.
If successful, the sweetened $60B cash/stock offer would mark the largest-ever Japanese acquisition of a western firm and propel Takeda into the top-ranks of global drug companies.
Takeda notes the improved bid represents a 58 percent premium over the closing price of Shire shares on March 23, the day before rumors surfaced about a takeover bid.
It said that completion of the deal would give Shire shareholders "a very meaningful stake in a leading global biopharmaceutical company" and benefits from the synergies flowing from the deal.
Shire is considering Takeda's latest bid.
Finsbury's London team of James Murgatroyd Rollo Head and Anjali Unnikrishnan are working the Takeda bid with Kal Goldberg and Chris Ryall in New York.
How purpose-driven communications strengthens reputation, rallies stakeholders and builds value during economically turbulent times.
Why healthcare must prioritize more strategic communications integration.
How the rules of the game are being rewritten in today’s turbulent health advocacy communications environment.
A PR and IR playbook for navigating the world’s largest annual investor meeting for life sciences companies.
Organizations navigating today’s health ecosystem face an increasingly difficult challenge: knowing when to speak publicly and when to stay silent on contentious cultural and political issues.
